During Pharmaceutical Production
New Roche Mycoplasma PCR Test Replaces Time-Consuming Culture Testing / MycoTOOL PCR Test approved by EMEA
MycoTOOL is now globally available for use as a Mycoplasma PCR release test for pharmaceutical products. The test kit provides all critical reagents for performing an easy to use sample preparation and PCR.
Mollicutes / Mycoplasmas are frequent causes of contamination in biopharmaceutical production, cell therapy and tissue engineering. Traditional detection methods required by pharmacopoeias and regulatory authorities worldwide use growth on culture media to detect Mollicutes contamination. These culture-based techniques are time consuming and require a minimum of 28 days to complete. Furthermore, the cultivation of certain Mollicutes species may not be possible. Rapid microbial tests are urgently needed to facilitate faster detection and more rapid corrective action.
As an integrated pharmaceutical and diagnostic company, Roche has developed and implemented PCR testing for pharmaceutical processes. A specific quality of reagents, that is guaranteed to be nucleic acid free according to the current Quality Control procedures, allows a new level of sensitivity. The design and the production process for the MycoTOOL PCR test are monitored via change control notification within the state of the art Roche quality system, ensuring that the product will retain its proven high quality.
Roche Diagnostics Deutschland GmbH
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com
Press releases you might also be interested in
Weitere Informationen zum Thema "Biotechnik":
Hitachi Vantara Labs beschleunigt Modell-Implementierung
Die Hitachi Vantara Labs haben neue Funktionen zur Machine-Learning-Orchestrierung vorgestellt. Sie sollen beim Überprüfen, Testen, Neu-Trainieren und Re-Implementieren von Modellen in Produktionsumgebungen helfen.Weiterlesen